Spyre Therapeutics (NASDAQ:SYRE) Upgraded at Wall Street Zen

Posted by Brian Himes on Oct 6th, 2026

Wall Street Zen upgraded shares of Spyre Therapeutics (NASDAQ:SYRE – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

A number of other equities analysts have also issued reports on SYRE. Wedbush reiterated an “outperform” rating and set a $123.00 target price on shares of Spyre Therapeutics in a research report on Wednesday, September 9th. Mizuho raised their price target on shares of Spyre Therapeutics from $84.00 to $120.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Wells Fargo & Company boosted their price objective on shares of Spyre Therapeutics from $90.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Guggenheim upped their price objective on Spyre Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Spyre Therapeutics in a research report on Tuesday, September 1st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $109.71.

Get Our Latest Stock Analysis on SYRE

Spyre Therapeutics Stock Down 0.5%

Spyre Therapeutics stock opened at $92.72 on Friday. The stock has a 50-day simple moving average of $95.57 and a 200 day simple moving average of $82.04. Spyre Therapeutics has a 12-month low of $15.86 and a 12-month high of $110.18. The stock has a market capitalization of $8.15 billion, a price-to-earnings ratio of -47.55 and a beta of 3.10.

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.40. As a group, sell-side analysts anticipate that Spyre Therapeutics will post -2.71 EPS for the current year.

Insider Buying and Selling at Spyre Therapeutics

In related news, CEO Cameron Turtle sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $92.01, for a total transaction of $1,380,150.00. Following the completion of the sale, the chief executive officer directly owned 537,540 shares of the company’s stock, valued at $49,459,055.40. The trade was a 2.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott Burrows sold 7,500 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $91.83, for a total transaction of $688,725.00. Following the completion of the transaction, the chief financial officer owned 79,762 shares in the company, valued at $7,324,544.46. This represents a 8.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 183,564 shares of company stock worth $16,903,193 in the last 90 days. Corporate insiders own 15.69% of the company’s stock.

Institutional Trading of Spyre Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC increased its stake in shares of Spyre Therapeutics by 26.8% in the 2nd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $59,000 after acquiring an additional 140 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in Spyre Therapeutics during the 2nd quarter worth approximately $31,000. Summit Securities Group LLC bought a new position in Spyre Therapeutics during the 1st quarter worth approximately $28,000. Royal Bank of Canada grew its holdings in Spyre Therapeutics by 63.5% during the first quarter. Royal Bank of Canada now owns 3,250 shares of the company’s stock valued at $164,000 after purchasing an additional 1,262 shares during the period. Finally, KBC Group NV acquired a new position in Spyre Therapeutics during the first quarter valued at approximately $69,000. Institutional investors own 80.39% of the company’s stock.

Spyre Therapeutics Company Profile

(Get Free Report)

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody therapeutics for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. The company is working to create next-generation biologic medicines intended to address significant treatment needs in these chronic gastrointestinal conditions.

Spyre’s pipeline includes programs directed at validated inflammatory pathways, including interleukin-23 (IL-23) and tumor necrosis factor-like ligand 1A (TL1A).